52 results about "Hepatic parenchymal cell" patented technology

The invention relates to gardenia polysaccharide as well as a preparation method and application thereof. The gardenia polysaccharide comprises the following monosaccharide units: rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose, or mainly comprises rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose; the molar ratio of rhamnose to glucuronic acid to galacturonic acid to glucose to galactose to arabinose in the gardenia polysaccharide is (3-15): (1-8): (4-18): (1-6): (15-35): (25-70). According to the gardenia polysaccharide, FFA induced mouse primary parenchymal hepatic cell lipid accumulation can be reduced, no obvious cytotoxic effect exists, CDAHFD diet induced hepatic fibrosis can be reduced, and the gardenia polysaccharide has a good effect of preventing and / or treating non-alcoholic steatohepatitis.

The invention discloses a method for simultaneously extracting multiple types of cells from the same liver tissue, which is characterized by comprising the following steps: preparing a single-cell suspension; extracting parenchymal hepatic cells; extracting bile duct epithelial cells; extracting hepatic stellate cells; wherein the extraction step of the parenchymal hepatic cells, the bile duct epithelial cells and the hepatic stellate cells is carried out step by step according to the sequence. According to the technical scheme, efficient extraction of liver tissue cells and culture of functional organoid are achieved, various defects in the prior art are overcome, meanwhile, the technical scheme has a wide application range and is suitable for various liver tissues, and important technical support is provided for research and treatment of liver diseases.

The invention discloses a pharmaceutical composition containing a hiHeps-derived exosome, an application of the pharmaceutical composition or the hiHeps-derived exosome in preparation of a medicine for treating liver diseases, and an application of the pharmaceutical composition or the hiHeps-derived exosome in preparation of a medicine for reducing inflammation. The pharmaceutical composition comprises an exosome, a liposome and a nucleic acid drug, wherein the exosome is derived from hiHeps. The pharmaceutical composition can realize better nucleic acid delivery, has lower immunotoxicity and better biocompatibility compared with single cationic liposome delivery, and can efficiently realize expression and functions in in-vitro cell lines, primary hepatocytes and in-vivo mice. Compared with other exosomes, the pharmaceutical composition constructed by the hiHeps exosome also has higher liver targeting property and parenchymal hepatic cell targeting property.

The invention belongs to the technical field of medicines, and particularly relates to application of isosalicin in preparation of liver injury medicines. The invention provides the application of the isosalicin in the aspect of preparing the liver injury medicine for the first time. The isosalicin is isosalicin (the molecular formula is C13H18O7; the compound has a molecular weight of 286.28, hereinafter referred to as IS), and the medicine IS does not show toxicity in an investigated concentration range (6.25-100 [mu] M), can significantly improve the cell survival rate of acetaminophen induced damaged parenchymal hepatic cells AML-12 at the investigated concentration of 6.25-25 [mu] M, has a significant liver protection effect, and has a good application prospect in preparation of medicines for preventing and treating liver injury.

The application discloses a preparation method and application of large-size human liver organoids, and belongs to the technical field of cell culture. In the application, 2D culture mature human primary liver parenchymal cells with different cell amounts are resuspended by using a hepatocyte maturation medium HIM, and are added into a U-shaped bottom 96-hole plate for low-oxygen static culture. After the cells are aggregated, the cells are cultured in normal oxygen and are shaken, so that large-size human liver organoids with different cell contents are prepared. The method does not need biological materials, and can induce human primary liver parenchymal cells to self-assemble and construct functional liver organoids with high uniformity in scale through specific culture conditions. The method solves the problems of large batch difference, high heterogeneity and dedifferentiation in the prior art, and can be widely applied to drug hepatotoxicity testing, in-vitro modeling of liver diseases and development of a bioartificial liver system.

The invention discloses an application of anethomycin in preparation of a medicine for treating hereditary hemochromatosis. The anethomycin has the effect of promoting liver hepcidin expression, so that the liver iron level is reduced, and the anethomycin is used for treating hereditary hemosis. The research on the action mechanism of the anethomycin shows that the anethomycin promotes parenchymal hepatic cells to secrete hepcidin by up-regulating the expression of a key regulatory factor BMP6 of hepcidin expressed by hepatic sinus endothelial cells, so that the treatment application of hereditary hemochromia is realized, and the anethomycin has good commercial application prospects and scientific research values.

The invention particularly discloses a medicine for treating hereditary liver diseases and application thereof, and relates to the technical field of gene therapy. The invention provides a lipid nanoparticle containing alanine glyoxylate aminotransferase mRNA (messenger Ribonucleic Acid). The lipid nanoparticle comprises an mRNA solution and a lipid mixed solution, the concentration ratio of the mRNA solution to the lipid mixed solution is 1: (20-120). According to the lipid nanoparticles provided by the invention, the problem that the parenchymal hepatic cell AGT enzyme of a patient with primary type 1 hyperoxaluria is deficient is solved, the AGT mRNA delivery efficiency is further improved, and the urine oxalate reduction effect of a protein replacement therapy is improved. The invention provides a theoretical basis and an experimental basis for developing a new treatment strategy, and has good clinical transformation and clinical application prospects.

The present application relates to a kind of FAPi, FAPi intermediate, FAPi modified HSP47siRNA loaded lipid nanoparticles and its application, belong to the field of biological medicine.The inventor constructs a kind of HSP47siRNA loaded lipid nanoparticles (FAPi-LNP / siHSP47) of Fibroblast activation protein inhibitor (FAPi) modification in view of the problems of high morbidity of existing technology liver fibrosis, so far no medicine, and ordinary LNP mainly target delivery to liver parenchymal cell after intravenous injection, and cannot enter the activated hepatic stellate cell (HSC) that plays a key role in the development of liver fibrosis.The expression of HSP47 can be effectively knocked down by the mediation of the high expression of Fibroblast activation protein on the surface of activated HSC, and the content of liver fibrosis marker protein a-SMA can be reduced.Compared with LNP without FAPi modification, FAPi-LNP / siHSP47 actively targets activated HSC after entering liver tissue, enters cell under the mediation of FAP, significantly knocks down the expression of HSP47, reduces collagen deposition, and significantly improves liver fibrosis.

The invention relates to dual-targeting bionic hydrotalcite inorganic nanoparticles as well as a preparation method and application thereof. The preparation method comprises the following steps: obtaining a fresh erythrocyte membrane; obtaining an aged erythrocyte membrane; adding a fresh erythrocyte membrane and an aged erythrocyte membrane into the hydrotalcite inorganic nano-particles according to a certain proportion, mixing and stirring, and centrifuging to obtain the bionic hydrotalcite inorganic nano-particles. The dual-targeting bionic hydrotalcite inorganic nano-particles have the beneficial effects that the dual-targeting bionic hydrotalcite inorganic nano-particles have dual-targeting capability of being delivered to parenchymal hepatic cells and hepatic macrophages in a balanced manner, and oxidative stress and inflammatory response can be relieved at the same time.